Author: Timokratis Karamitros; Gethsimani Papadopoulou; Maria Bousali; Anastasios Mexias; Sotiris Tsiodras; Andreas Mentis
Title: SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies Document date: 2020_3_28
ID: jxm69ndw_3
Snippet: Importantly, intra-host genomic variability leads to antigenic variability, which is of higher importance, especially for pathogens that fail to elicit long-lasting immunity in their hosts, and remains a major contributor to the complexity of vaccine design [14] , [15] . To date, there are no clinically approved vaccines available for protection of general population from SARS-and MERS-CoV infections as there is no effective vaccine to induce rob.....
Document: Importantly, intra-host genomic variability leads to antigenic variability, which is of higher importance, especially for pathogens that fail to elicit long-lasting immunity in their hosts, and remains a major contributor to the complexity of vaccine design [14] , [15] . To date, there are no clinically approved vaccines available for protection of general population from SARS-and MERS-CoV infections as there is no effective vaccine to induce robust cell mediated and humoral immune responses [16] , [17] .
Search related documents:
Co phrase search for related documents- antigenic variability and humoral immune response: 1
- antigenic variability and immune response: 1, 2, 3, 4, 5
- antigenic variability and vaccine design: 1, 2, 3
- effective vaccine and general population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- effective vaccine and general population protection: 1, 2
- effective vaccine and high importance: 1
- effective vaccine and humoral immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- effective vaccine and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- effective vaccine and major contributor: 1, 2
- effective vaccine and robust cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- effective vaccine and vaccine design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- general population and high importance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- general population and humoral immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- general population and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- general population and long last: 1, 2, 3
- general population and major contributor: 1, 2, 3
- general population and robust cell: 1, 2, 3
- general population and vaccine design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- general population protection and humoral immune response: 1
Co phrase search for related documents, hyperlinks ordered by date